Filing Flows

Filing Flows › Companies › Tenaya Therapeutics › Cash flow

Tenaya Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$17.7M in Q3 2026 · −$54.6M over twelve months

Operating cash flow−$17.7M
Free cash flow−$17.7M

Analysis

In Q3 2026, Tenaya Therapeutics generated −$17.7M of operating cash flow. That is $2.1M less than in Q3 2025 (−$15.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$54.4M; the largest uses were operating cash flow ($54.4M), capital spending ($237K); besides operations, cash came from other financing ($65.1M), other investing ($26K); the cash balance rose by $10.5M.

Operating cash flow was −$17.7M against net income of −$18.9M. The largest differences: stock-based pay +$1.7M, deferred revenue −$1.1M, payables +$758K.

Free cash flow

Tenaya Therapeutics: free cash flow by quarterTenaya Therapeutics: free cash flow by quarter−$18.6MQ4 2024−$23.5MQ1 2025−$15.8MQ2 2025−$15.6MQ3 2025−$14.0MQ4 2025−$19.2MQ1 2026−$3.7MQ2 2026−$17.7MQ3 2026
Operating cash flow less capital spending.
Tenaya Therapeutics: operating cash flow against capital spendingTenaya Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$18.4M$204KQ4 2024−$23.1M$383KQ1 2025−$15.6M$142KQ2 2025−$15.6M$26KQ3 2025−$13.9M$67KQ4 2025−$19.2M$11KQ1 2026−$3.6M$159KQ2 2026−$17.7M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$17.7M, Capital spending $0.

Capital allocation, year by year

Tenaya Therapeutics: where the cash came from (up) and went (down), by fiscal yearTenaya Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingBuybacksFY2021: Operating cash flow −$60.8MFY2021: Shares issued $189MFY2021: Capital spending −$25.1MFY2021: Buybacks −$13K$189MFY2021FY2022: Operating cash flow −$104MFY2022: Shares issued $77.4MFY2022: Capital spending −$20.6M$77.4MFY2022FY2023: Operating cash flow −$102MFY2023: Shares issued $3.9MFY2023: Capital spending −$1.2M$3.9MFY2023FY2024: Operating cash flow −$90.5MFY2024: Shares issued $46.8MFY2024: Capital spending −$1.0M$46.8MFY2024FY2025: Operating cash flow −$68.3MFY2025: Capital spending −$618KFY2025
Over these 5 years operating cash flow totalled −$426M; the largest uses were operating cash flow ($426M) and capital spending ($48.6M). Cash-flow statements as filed.

Where the cash came from and went

Tenaya Therapeutics: sources (+) and uses (−) of cash, Q3 2026Tenaya Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$17.7MCash drawn (+) / kept (−)$11.3MOther financing$6.4MOther investing$26K
Tenaya Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Tenaya Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$65.1MOperating cash flow−$54.4MCash drawn (+) / kept (−)−$10.5MCapital spending−$237KOther investing$26K

From profit to cash

Tenaya Therapeutics: net income to operating cash flow, Q3 2026Tenaya Therapeutics: net income to operating cash flow, Q3 2026Net income−$18.9MDepreciation & amortization$394KStock-based pay$1.7MImpairments$666KGains on disposals$89KOther non-cash$87KReceivables−$17KPayables$758KDeferred revenue−$1.1MOperating cash flow−$17.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingCash drawn (+) / kept (−)Free cash flow
Q3 2026−$17.7M—$11.3M−$17.7M
Q2 2026−$3.6M−$159K$2.8M−$3.7M
Q1 2026−$19.2M−$11K$19.7M−$19.2M
Q4 2025−$13.9M−$67K−$44.2M−$14.0M
Q3 2025−$15.6M−$26K$6.4M−$15.6M
Q2 2025−$15.6M−$142K−$8.9M−$15.8M
Q1 2025−$23.1M−$383K−$49.4M−$23.5M
Q4 2024−$18.4M−$204K$3.9M−$18.6M

Tenaya Therapeutics: income statement and cash flow

Tenaya Therapeutics, Q3 2026: revenue $1.7M. The chart follows the revenue to costs, profit and cash.

Tenaya Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.